Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis

作者：Dai, Di; Dong, Xi-Hua; Cheng, Shi-Tong; Zhu, Ge; Guo, Xiao-Lin^*

来源：Tumor Biology, 2014, 35(8): 8209-8216.

DOI：10.1007/s13277-014-2055-1

• HIN-1
• Promoter methylation
• Breast cancer
• Meta-analysis

We conducted the present meta-analysis of relevant cohort studies to evaluate whether promoter methylation of the high in normal-1 (HIN-1) gene contributes to breast cancer. The MEDLINE (1966 similar to 2013), Cochrane Library (Issue 12, 2013), EMBASE (1980 similar to 2013), CINAHL (1982 similar to 2013), Web of Science (1945 similar to 2013), and Chinese Biomedical (CBM) (1982 similar to 2013) databases were searched without any language restrictions. Meta-analyses were conducted using Stata software (version 12.0; Stata Corporation, College Station, TX, USA). Crude odds ratios (ORs) with their 95 % confidence interval (CI) were calculated. Nine clinical cohort studies that enrolled a total of 693 breast cancer patients were included in the meta-analysis. The results of our meta-analysis demonstrated that HIN-1 methylation frequency in cancer tissue was significantly higher than that of normal and benign tissues (cancer tissue vs. normal tissue: OR = 52.60, 95 % CI = 33.77 similar to 81.92, P < 0.001; cancer tissue vs. benign tissue: OR = 2.38, 95 % CI = 1.53 similar to 3.70, P < 0.001; respectively). Ethnicity-stratified analysis indicated that HIN-1 promoter methylation was correlated with the pathogenesis of breast cancer among both Asians and Caucasians (all P < 0.05). Our findings provide empirical evidence that aberrant HIN-1 promoter methylation may contribute to the pathogenesis of breast cancer. Thus, aberrant HIN-1 promoter methylation could be an independent and important biomarker used in predicting the prognosis and progression of breast cancer.

• 出版日期2014-8
• 单位中国医科大学